Iraksin

Liothyronine Sodium, the active ingredient in Iraksin, is a synthetic thyroid hormone presented as an oral tablet for oral use. It is employed in the management of hypothyroidism and related conditions, providing rapid physiological replacement of triiodothyronine (T3) in adult patients with deficient thyroid function.

GNH USA supplies Iraksin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. GNH USA also offers comprehensive regulatory support and logistics coordination for cross‑border shipments.

Liothyronine sodium (Iraksin) is a synthetic thyroid hormone used to replace deficient T3 in thyroid‑related disorders.

- Hypothyroidism: restores normal metabolic rate by supplementing deficient triiodothyronine. - Myxedema: alleviates severe hypothyroid symptoms by providing rapid T3 replacement. - Thyroid hormone replacement therapy: maintains euthyroid state in patients requiring supplemental T3. - Congenital hypothyroidism: supports early thyroid hormone levels in newborns with deficient T3 production.

Liothyronine sodium may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate headache may occur. - Insomnia: difficulty sleeping or altered sleep patterns. - Palpitations: sensation of rapid or irregular heartbeat. - Sweating: increased perspiration. - Tremor: fine shaking of hands or limbs. - Nausea: upset stomach or feeling of queasiness.

Serious or Rare Side Effects: - Cardiac arrhythmia: abnormal heart rhythm that may require medical attention. - Angina pectoris: chest pain due to reduced coronary blood flow. - Heart failure exacerbation: worsening of existing heart failure symptoms. - Severe hyperthyroidism: signs of over‑replacement such as heat intolerance and weight loss. - Anaphylactic reaction: rare allergic response with rash, swelling, or breathing difficulty. - Osteoporosis: accelerated bone loss with long‑term high‑dose therapy.

When using liothyronine sodium, several precautions should be observed to ensure safe therapy.

- Dose adjustment: tailor dose in elderly or cardiac patients. - Thyroid function monitoring: regularly assess TSH and T3 levels. - Cardiovascular disease: use cautiously in patients with coronary artery disease. - Pregnancy and lactation: evaluate risk–benefit, limited data available. - Drug interactions: review concomitant medications that affect thyroid hormone metabolism. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in original container.

Liothyronine sodium can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Amiodarone: may alter thyroid hormone levels and increase toxicity. - Antithyroid drugs (methimazole, propylthiouracil): antagonize therapeutic effect. - Estrogen therapy: raises thyroid‑binding globulin, potentially requiring dose adjustment. - Beta‑blockers: may mask symptoms of excess thyroid hormone, careful monitoring required.

Moderate Interactions (Monitor Closely): - Warfarin: thyroid hormones may enhance anticoagulant effect, monitor INR. - Phenytoin, carbamazepine, rifampin: increase hepatic metabolism, may lower liothyronine levels. - Digoxin: increased risk of toxicity with excess thyroid hormone; monitor levels. - Corticosteroids: increase metabolism of liothyronine, may reduce efficacy.